Heart Cell Therapy Cuts Angina by 82% and Boosts Exercise Stamina for Two Years
BioCardia's bone marrow cell therapy shows lasting gains in exercise tolerance and dramatic angina reduction in chronic heart disease patients.
Summary
BioCardia's CardiAMP therapy, which uses a patient's own bone marrow cells delivered via catheter, showed significant improvements in heart disease patients over two years. In a clinical trial for chronic myocardial ischemia — reduced blood flow to the heart — patients gained nearly three extra minutes of exercise capacity on average, and angina episodes dropped by 82% at six months. These benefits held through the two-year follow-up with no major adverse cardiac events reported. All participants had already exhausted standard treatments, making these results particularly notable. The therapy holds FDA Breakthrough Therapy designation for ischemic heart failure and is currently investigational in the US.
Detailed Summary
Chronic myocardial ischemia is a condition where the heart muscle doesn't receive enough blood, causing chest pain, fatigue, and severely limited physical activity. For patients who've already tried all standard treatments without adequate relief, options are few. BioCardia's CardiAMP cell therapy is attempting to change that with a regenerative approach that uses the patient's own biology to heal damaged heart tissue.
Presented at EuroPCR in Paris in May 2026, preliminary results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia trial showed meaningful and durable improvements. Patients gained an average of 179 seconds — nearly three minutes — in exercise tolerance, a gain that was sustained at the two-year follow-up. Angina episodes, which are episodes of chest pain caused by reduced blood flow, dropped by an average of 82% at six months post-treatment. No treatment-related major adverse cardiac events were recorded throughout the study period.
CardiAMP is an autologous therapy, meaning it uses cells harvested from each patient's own bone marrow. These cells are delivered directly to the heart via a minimally invasive catheter procedure, reducing the risks associated with open surgery. The therapy carries FDA Breakthrough Therapy designation for ischemic heart failure, signaling the agency's recognition of its potential to address a serious unmet medical need.
For health-conscious adults, these findings underscore the growing role of regenerative and cell-based therapies in cardiovascular medicine. Conditions like ischemic heart disease are among the leading causes of reduced healthspan and premature death globally, and innovations that restore functional capacity — especially exercise tolerance — have direct implications for longevity.
Important caveats apply. This is an open-label, preliminary report from the company itself, not yet peer-reviewed. The trial lacks a placebo comparison in this cohort, and the therapy remains investigational in the United States. Independent verification is needed before drawing firm conclusions.
Key Findings
- Exercise tolerance improved by an average of 179 seconds, sustained through two years of follow-up.
- Angina episodes reduced by 82% at six months post-treatment in chronic ischemia patients.
- No treatment-emergent major adverse cardiac events reported across the study period.
- CardiAMP uses autologous bone marrow cells, minimizing rejection risk via a catheter-based delivery.
- Therapy holds FDA Breakthrough Therapy designation for ischemic heart failure, signaling unmet need recognition.
Methodology
This is a news report summarizing company-presented preliminary data from an open-label clinical trial, shared at EuroPCR 2026. The findings originate from BioCardia itself and have not yet been independently peer-reviewed or published in a journal. Evidence basis is a single-arm, open-label cohort, limiting the ability to attribute results solely to the therapy.
Study Limitations
Results are preliminary, open-label, and company-reported — no peer-reviewed publication was referenced. The absence of a concurrent placebo-controlled arm limits causal certainty. Readers should await independent analysis and full trial data before drawing firm clinical conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.